125 related articles for article (PubMed ID: 38291671)
1. Incidence of pulmonary toxicity in bleomycin-containing regimens for testicular cancer with and without the use of growth factor.
McAvoy C; Fields P; Otto D; Kreimer A; Ellis CS
J Oncol Pharm Pract; 2024 Jan; ():10781552231225766. PubMed ID: 38291671
[TBL] [Abstract][Full Text] [Related]
2. Pulmonary toxicity in patients with advanced-stage germ cell tumors receiving bleomycin with and without granulocyte colony stimulating factor.
Saxman SB; Nichols CR; Einhorn LH
Chest; 1997 Mar; 111(3):657-60. PubMed ID: 9118704
[TBL] [Abstract][Full Text] [Related]
3. Radiotherapy does not influence the severe pulmonary toxicity observed with the administration of gemcitabine and bleomycin in patients with advanced-stage Hodgkin's lymphoma treated with the BAGCOPP regimen: a report by the German Hodgkin's Lymphoma Study Group.
Macann A; Bredenfeld H; Müller RP; Diehl V; Engert A; Eich HT
Int J Radiat Oncol Biol Phys; 2008 Jan; 70(1):161-5. PubMed ID: 17855012
[TBL] [Abstract][Full Text] [Related]
4. Febrile neutropenia (FN) and pegfilgrastim prophylaxis in breast cancer and non-Hodgkin's lymphoma patients receiving high (> 20%) FN-risk chemotherapy: results from a prospective observational study.
Salmon JP; Smakal M; Karanikiotis C; Wojtukiewicz MZ; Omnes Y; DeCosta L; Wetten S; O'Kelly J
Support Care Cancer; 2019 Apr; 27(4):1449-1457. PubMed ID: 30259136
[TBL] [Abstract][Full Text] [Related]
5. The Use of Filgrastim in Patients with Hodgkin Lymphoma Receiving ABVD.
Binder AF; Rai S; Steinberg A
Int J Hematol Oncol Stem Cell Res; 2017 Oct; 11(4):286-292. PubMed ID: 29340124
[No Abstract] [Full Text] [Related]
6. Bleomycin in Hodgkin's Lymphoma - A Boon or a Bane? - A Retrospective Study of Bleomycin Pulmonary Toxicity in Hodgkin's Lymphoma.
Udupa CBK; Koteshwar P; Udupa KS
Indian J Palliat Care; 2019; 25(4):523-526. PubMed ID: 31673206
[TBL] [Abstract][Full Text] [Related]
7. Prognostic impact of bleomycin pulmonary toxicity on the outcomes of patients with germ cell tumors.
Maruyama Y; Sadahira T; Mitsui Y; Araki M; Wada K; Tanimoto R; Kobayashi Y; Watanabe M; Watanabe T; Nasu Y
Med Oncol; 2018 Apr; 35(6):80. PubMed ID: 29700638
[TBL] [Abstract][Full Text] [Related]
8. Observational study of the prevalence of febrile neutropenia in patients who received filgrastim or pegfilgrastim associated with 3-4 week chemotherapy regimens in community oncology practices.
Morrison VA; Wong M; Hershman D; Campos LT; Ding B; Malin J
J Manag Care Pharm; 2007 May; 13(4):337-48. PubMed ID: 17506600
[TBL] [Abstract][Full Text] [Related]
9. Bleomycin-Induced Pulmonary Changes on Restaging Computed Tomography Scans in Two Thirds of Testicular Cancer Patients Show No Correlation With Fibrosis Markers.
den Hollander MW; Westerink ND; Lubberts S; Bongaerts AH; Wolf RF; Altena R; Nuver J; Oosting SF; de Vries EG; Walenkamp AM; Meijer C; Gietema JA
Oncologist; 2016 Aug; 21(8):995-1001. PubMed ID: 27328932
[TBL] [Abstract][Full Text] [Related]
10. First-line treatment with brief-duration chemotherapy plus rituximab in elderly patients with intermediate-grade non-Hodgkin's lymphoma: phase II trial.
Hainsworth JD; Litchy S; Lamb MR; Rodriguez GI; Scroggin C; Greco FA
Clin Lymphoma; 2003 Jun; 4(1):36-42. PubMed ID: 12837153
[TBL] [Abstract][Full Text] [Related]
11. Analysis of the Safety of Pegfilgrastim Addition in Bleomycin, Etoposide, and Cisplatin Treatment Patients With Germ Cell Tumors.
Nakagawa R; Iwamoto H; Makino T; Kadomoto S; Yaegashi H; Iijima M; Kawaguchi S; Nohara T; Shigehara K; Izumi K; Kadono Y; Mizokami A
Front Oncol; 2021; 11():770067. PubMed ID: 35070973
[TBL] [Abstract][Full Text] [Related]
12. Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin's lymphoma.
Martin WG; Ristow KM; Habermann TM; Colgan JP; Witzig TE; Ansell SM
J Clin Oncol; 2005 Oct; 23(30):7614-20. PubMed ID: 16186594
[TBL] [Abstract][Full Text] [Related]
13. G-CSF use in patients receiving first-line chemotherapy for non-Hodgkin's lymphoma (NHL) and granulocyte-colony stimulating factors (G-CSF) as observed in clinical practice in Italy.
Vitolo U; Angrili F; DeCosta L; Wetten S; Federico M
Med Oncol; 2016 Dec; 33(12):139. PubMed ID: 27822615
[TBL] [Abstract][Full Text] [Related]
14. Cost-benefit of granulocyte colony-stimulating factor administration in older patients with non-Hodgkin's lymphoma treated with combination chemotherapy.
Zagonel V; Babare R; Merola MC; Talamini R; Lazzarini R; Tirelli U; Carbone A; Monfardini S
Ann Oncol; 1994; 5 Suppl 2():127-32. PubMed ID: 7515645
[TBL] [Abstract][Full Text] [Related]
15. Intermittent granulocyte colony-stimulating factor maintains dose intensity after ABVD therapy complicated by neutropenia.
Ho P; Sherman P; Grigg A
Eur J Haematol; 2012 May; 88(5):416-21. PubMed ID: 22296221
[TBL] [Abstract][Full Text] [Related]
16. Impact of Granulocyte-colony Stimulating Factor on Bleomycin-induced Pneumonitis in Chemotherapy-treated Germ Cell Tumors.
Kwan EM; Beck S; Amir E; Jewett MA; Sturgeon JF; Anson-Cartwright L; Chung PW; Warde PR; Moore MJ; Bedard PL; Tran B
Clin Genitourin Cancer; 2017 Sep; ():. PubMed ID: 28943331
[TBL] [Abstract][Full Text] [Related]
17. Patterns of primary prophylactic granulocyte colony-stimulating factor use in older Medicare patients with cancer receiving myelosuppressive chemotherapy.
Schenfeld J; Gong T; Henry D; Kelsh M; Gawade P; Peng Y; Bradbury BD; Li S
Support Care Cancer; 2022 Jul; 30(7):6327-6338. PubMed ID: 35482126
[TBL] [Abstract][Full Text] [Related]
18. Serum creatinine level during chemotherapy for testicular cancer as a possible predictor of bleomycin-induced pulmonary toxicity.
Kawai K; Hinotsu S; Tomobe M; Akaza H
Jpn J Clin Oncol; 1998 Sep; 28(9):546-50. PubMed ID: 9793027
[TBL] [Abstract][Full Text] [Related]
19. Frequency and risk factors of bleomycin-induced pulmonary toxicity in South Indian patients with germ-cell tumors.
Thakkar DN; Ramasamy K; Adithan S; Selvarajan S; Dubashi B
J Cancer Res Ther; 2021; 17(2):443-449. PubMed ID: 34121690
[TBL] [Abstract][Full Text] [Related]
20. Effect of granulocyte colony-stimulating factor on bleomycin-induced acute lung injury and pulmonary fibrosis.
Azoulay E; Herigault S; Levame M; Brochard L; Schlemmer B; Harf A; Delclaux C
Crit Care Med; 2003 May; 31(5):1442-8. PubMed ID: 12771616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
